Weekly Recap

Phase 3 LIGHTHOUSE Study Initiated, Trend Toward ASMs With Lower Teratogenic Risk, Rituximab Effects on NMOSD, MOGAD

ByNeurologyLive® Staff

October 15th 2022

Neurology News Network for the week ending October 15, 2022. [WATCH TIME: 3 minutes]

Ublituximab Outperforms Teriflunomide on ARRs, CNM-Au8 Fails HEALEY ALS Trial, Benefits of Aerobic Exercise in Multiple Sclerosis

ByNeurologyLive® Staff

October 8th 2022

Neurology News Network for the week ending October 8, 2022. [WATCH TIME: 3 minutes]

Verdiperstat Fails ALS Study, Lecanemab Shines in Latest Phase 3 Findings, Ofatumumab Continues Superiority Over Teriflunomide

ByNeurologyLive® Staff

October 1st 2022

Neurology News Network for the week ending October 1, 2022. [WATCH TIME: 4 minutes]

Rituximab as Initial gMG Treatment, WVE-003 Proves Positive in HD, and Incidence of Guillian-Barré After COVID-19 Vaccination

ByNeurologyLive® Staff

September 24th 2022

Neurology News Network for the week ending September 24, 2022. [WATCH TIME: 4 minutes]

Abnormal Vascular Hemodynamics Linked With Tau, Constant Therapy Shows Feasibility in Alzheimer Disease, LIFT-AD Study Amended

ByNeurologyLive® Staff

September 17th 2022

Neurology News Network for the week ending September 17, 2022. [WATCH TIME: 4 minutes]

New Study on COVID-19 Vaccinations in MS, FDA Lifts Hold on SRP-5051, Implantable Loop Recorder and Atrial Fibrillation

ByNeurologyLive® Staff

September 10th 2022

Neurology News Network for the week ending September 10, 2022. [WATCH TIME: 4 minutes]

FDA Approves Auotinjector for Status Epilepticus, Penumbra System Removes Clots in Ischemic Stroke, Tobacco Use Correlated With Cognitive Decline

ByNeurologyLive® Staff

September 3rd 2022

Neurology News Network for the week ending September 3, 2022. [WATCH TIME: 4 minutes]

Remote Ischemic Conditioning Improves Post Stroke Outcomes, Opiate Use High in Idiopathic Intracranial Hypertension, Drug Resistant Epilepsy and Increased Mortality

ByNeurologyLive® Staff

August 27th 2022

Neurology News Network for the week ending August 27, 2022. [WATCH TIME: 4 minutes]

Results of VISIONARY-MS Study Released, Analysis Complete for Concussion Therapy OXE103, Chronic Kidney Disease Associated With Intracerebral Hemorrhage

ByNeurologyLive® Staff

August 20th 2022

Neurology News Network for the week ending August 20, 2022. [WATCH TIME: 4 minutes]

Stigma Adds to Depressive Symptoms in Epilepsy, Parkinson Disease and Diabetes Show Increased Neuroaxonal Damage, ICER Publishes Report on ALS Treatments

ByNeurologyLive® Staff

August 13th 2022

Neurology News Network for the week of August 13, 2022. [WATCH TIME: 4 minutes]

Severe Preeclampsia Linked With Neuroinflammation, Neurofilament Light Associated With Memory Function, Discrimination Effects on Cognition

ByNeurologyLive® Staff

August 6th 2022

Neurology News Network for the week ending August 6, 2022. [WATCH TIME: 4 minutes]

FDA Accepts NDA for Tofersen, Serious Falls Increased With Hypnotic Medications, Racial Disparities in Sleep of Pregnant Women

ByNeurologyLive® Staff

July 30th 2022

Neurology News Network for the week ending July 30, 2022. [WATCH TIME: 4 minutes]

CNM-Au8 Reduces Mortality in ALS, Prenatal Exposure to ASMs Increases Neurodevelopmental Disorders, FDA Grants Tentative Approval to FT218

ByNeurologyLive® Staff

July 23rd 2022

Neurology News Network for the week ending July 23, 2022. [WATCH TIME: 4 minutes]

Apitegromab Continues Positive Efficacy in SMA, Alzheimer Disease Risk Reduced Through Lifestyle Factors, Depressive Trajectories Predict Stroke Risk

ByNeurologyLive® Staff

July 16th 2022

Neurology News Network for the week ending July 16, 2022. [WATCH TIME: 4 minutes]

FDA Grants Priority Review for Lecanemab, FDA AdComm to Reconvene on AMX0035, Tolebrutinib Trials Suspended Over Safety

ByNeurologyLive® Staff

July 9th 2022

Neurology News Network for the week ending July 9, 2022. [WATCH TIME: 4 minutes]

Ocrelizumab Reduces Thalamic Volume Loss, Cenobamate Shines in C017 Study, Trial of LRRK2 Inhibitor BIIB122 Commences

ByNeurologyLive® Staff

July 2nd 2022

Neurology News Network for the week ending July 2, 2022. [WATCH TIME: 4 minutes]

AbbVie Submits sNDA for Atogepant in Chronic Migraine, Semorinemab Fails in Phase 2 Prodromal Alzheimer Study, StrivePD Software Gets FDA Greenlight

ByNeurologyLive® Staff

June 25th 2022

Neurology News Network for the week ending June 25, 2022. [WATCH TIME: 4 minutes]

Erenumab Outperforms Topiramate in PROs, Atogepant Dose-Dependent With Weight Changes, Vutrisiran FDA-Approved for ATTR Amyloidosis

ByNeurologyLive® Staff

June 18th 2022

Neurology News Network for the week ending June 18, 2022. [WATCH TIME: 3 minutes]

6-Week Natalizumab Dosing Efficacious, MS Cognitive Perceptions, Glatiramer Acetate Depot Shines in Progressive MS

ByNeurologyLive® Staff

June 11th 2022

Neurology News Network for the week ending June 11, 2022. [WATCH TIME: 3 minutes]

AbbVie Submits NDA for ABBV-951, Periconceptional Folic Acid Supplementation Lowers Preterm Birth Risk, FDA Accepts NDA for Zavegepant

ByNeurologyLive® Staff

May 28th 2022

Neurology News Network for the week ending May 28, 2022.

Diazepam Increased Time Between Cluster Intervals, Higher Dose Nusinersen Shows Extra Benefit, Lecanemab BLA Submitted

ByNeurologyLive® Staff

May 21st 2022

Neurology News Network for the week ending May 21, 2022. [WATCH TIME: 4 minutes]

Ravulizumab Meets Primary End Point in NMOSD, Dosing Initiated in TRANQUILITY II Study, NIH Launches EBV Vaccine Trial

ByNeurologyLive® Staff

May 14th 2022

Neurology News Network for the week ending May 14, 2022. [WATCH TIME: 4 minutes]

Risdiplam Shows Safety at 3-Year Period, FDA Issues CRL for AXS-07, Cognitive Tests Improve Responder Profiles in MS

ByNeurologyLive® Staff

May 7th 2022

Neurology News Network for the week ending May 7, 2022. [WATCH TIME: 4 minutes]

Pitolisant Being Evaluated for Idiopathic Hypersomnia, FDA Approves Ravulizumab for Generalized Myasthenia Gravis, Gender Differences in MS Disease Activity

ByNeurologyLive® Staff

April 30th 2022

Neurology News Network for the week ending April 30, 2022. [WATCH TIME: 4 minutes]

Risk Factors Identified for Posttraumatic Seizures, Acupuncture Benefits in Insomnia, Erenumab Improves Migraine in Patients Unresponsive to Prophylactics

ByNeurologyLive® Staff

April 23rd 2022

Neurology News Network for the week ending April 23, 2022. [WATCH TIME: 3 minutes]

Vutrisiran FDA Decision Extended, Gamma Sensory Stimulation Shows Benefit in Alzheimer, DBS Programming Software Greenlit

ByNeurologyLive® Staff

April 16th 2022

Neurology News Network for the week ending April 16, 2022 [WATCH TIME: 3 minutes]

Once-Nightly Sodium Oxybate Preferred in Narcolepsy, ABBV-951 Shines in PD, Ocrelizumab Demonstrates Improved Cognitive Function in Progressive MS

ByNeurologyLive® Staff

April 9th 2022

Neurology News Network for the week ending April 9, 2022. [WATCH TIME: 4 minutes]

Biogen Submits Protocol for Phase 4 Aducanumab Study, FDA AdComm's Board Doesn't Recommend AMX0035 Approval, Intensive SBP Increases Cerebral Blood Flow

ByNeurologyLive® Staff

April 2nd 2022

Neurology News Network for the week ending April 2, 2022. [WATCH TIME: 3 minutes]

Tobacco Smoking Increases MS Risk, Autism Risk Increased in Pediatric Stroke, Zolgensma Improves Bulbar Function

ByMarco Meglio

March 26th 2022

Neurology News Network for the week ending March 26, 2022. [WATCH TIME: 4 minutes]

Initial Phase 4 RESPOND Results, Omaveloxolone Continues to Perform in FA, Wearable Sensors Safe for FSHD

ByNeurologyLive® Staff

March 19th 2022

Neurology News Network for the week ending March 19, 2022.

Weekly Recap

Phase 3 LIGHTHOUSE Study Initiated, Trend Toward ASMs With Lower Teratogenic Risk, Rituximab Effects on NMOSD, MOGAD

Ublituximab Outperforms Teriflunomide on ARRs, CNM-Au8 Fails HEALEY ALS Trial, Benefits of Aerobic Exercise in Multiple Sclerosis

Verdiperstat Fails ALS Study, Lecanemab Shines in Latest Phase 3 Findings, Ofatumumab Continues Superiority Over Teriflunomide

Rituximab as Initial gMG Treatment, WVE-003 Proves Positive in HD, and Incidence of Guillian-Barré After COVID-19 Vaccination

Abnormal Vascular Hemodynamics Linked With Tau, Constant Therapy Shows Feasibility in Alzheimer Disease, LIFT-AD Study Amended

New Study on COVID-19 Vaccinations in MS, FDA Lifts Hold on SRP-5051, Implantable Loop Recorder and Atrial Fibrillation

FDA Approves Auotinjector for Status Epilepticus, Penumbra System Removes Clots in Ischemic Stroke, Tobacco Use Correlated With Cognitive Decline

Remote Ischemic Conditioning Improves Post Stroke Outcomes, Opiate Use High in Idiopathic Intracranial Hypertension, Drug Resistant Epilepsy and Increased Mortality

Results of VISIONARY-MS Study Released, Analysis Complete for Concussion Therapy OXE103, Chronic Kidney Disease Associated With Intracerebral Hemorrhage

Stigma Adds to Depressive Symptoms in Epilepsy, Parkinson Disease and Diabetes Show Increased Neuroaxonal Damage, ICER Publishes Report on ALS Treatments

Severe Preeclampsia Linked With Neuroinflammation, Neurofilament Light Associated With Memory Function, Discrimination Effects on Cognition

FDA Accepts NDA for Tofersen, Serious Falls Increased With Hypnotic Medications, Racial Disparities in Sleep of Pregnant Women

CNM-Au8 Reduces Mortality in ALS, Prenatal Exposure to ASMs Increases Neurodevelopmental Disorders, FDA Grants Tentative Approval to FT218

Apitegromab Continues Positive Efficacy in SMA, Alzheimer Disease Risk Reduced Through Lifestyle Factors, Depressive Trajectories Predict Stroke Risk

FDA Grants Priority Review for Lecanemab, FDA AdComm to Reconvene on AMX0035, Tolebrutinib Trials Suspended Over Safety

Ocrelizumab Reduces Thalamic Volume Loss, Cenobamate Shines in C017 Study, Trial of LRRK2 Inhibitor BIIB122 Commences

AbbVie Submits sNDA for Atogepant in Chronic Migraine, Semorinemab Fails in Phase 2 Prodromal Alzheimer Study, StrivePD Software Gets FDA Greenlight

Erenumab Outperforms Topiramate in PROs, Atogepant Dose-Dependent With Weight Changes, Vutrisiran FDA-Approved for ATTR Amyloidosis

6-Week Natalizumab Dosing Efficacious, MS Cognitive Perceptions, Glatiramer Acetate Depot Shines in Progressive MS

AbbVie Submits NDA for ABBV-951, Periconceptional Folic Acid Supplementation Lowers Preterm Birth Risk, FDA Accepts NDA for Zavegepant

Diazepam Increased Time Between Cluster Intervals, Higher Dose Nusinersen Shows Extra Benefit, Lecanemab BLA Submitted

Ravulizumab Meets Primary End Point in NMOSD, Dosing Initiated in TRANQUILITY II Study, NIH Launches EBV Vaccine Trial

Risdiplam Shows Safety at 3-Year Period, FDA Issues CRL for AXS-07, Cognitive Tests Improve Responder Profiles in MS

Pitolisant Being Evaluated for Idiopathic Hypersomnia, FDA Approves Ravulizumab for Generalized Myasthenia Gravis, Gender Differences in MS Disease Activity

Risk Factors Identified for Posttraumatic Seizures, Acupuncture Benefits in Insomnia, Erenumab Improves Migraine in Patients Unresponsive to Prophylactics

Vutrisiran FDA Decision Extended, Gamma Sensory Stimulation Shows Benefit in Alzheimer, DBS Programming Software Greenlit

Once-Nightly Sodium Oxybate Preferred in Narcolepsy, ABBV-951 Shines in PD, Ocrelizumab Demonstrates Improved Cognitive Function in Progressive MS

Biogen Submits Protocol for Phase 4 Aducanumab Study, FDA AdComm's Board Doesn't Recommend AMX0035 Approval, Intensive SBP Increases Cerebral Blood Flow

Tobacco Smoking Increases MS Risk, Autism Risk Increased in Pediatric Stroke, Zolgensma Improves Bulbar Function

Initial Phase 4 RESPOND Results, Omaveloxolone Continues to Perform in FA, Wearable Sensors Safe for FSHD

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Dental Caries and Periodontal Disease Increase Ischemic Stroke Risk, Study Shows

Preliminary Phase 2 Data Support Therapeutic Development of Synaptic Regenerative Drug SPG302 in ALS

FDA Issues Complete Response Letter for Spinocerebellar Ataxia Agent Troriluzole

FDA Feedback Provides Clarity for Phase 3 Trial of Neflamapimod in Dementia With Lewy Bodies

Therapeutic Promise and Mechanism of DYNE-101 to Treat Myotonic Dystrophy: Doug Kerr, MD, PhD